Guggenheim Maintains Buy on IDEAYA Biosciences, Raises Price Target to $54

Benzinga Newsdesk www.benzinga.com Positive 70.8%

Neg 0% Neu 0% Pos 70.8%

Guggenheim analyst Paul Jeng maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and raises the price target from $50 to $54.